![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 6
2022
Biersching, T.; Schweda, A.; Oechsle, K.; Nauck, F.; Rosenbruch, J.; Schuler, U.; Hense, J.; Neukirchen, M.; Weber, M.; Junghanss, C.; Kramer, T.; Ostgathe, C.; Thuss-Patience, P.; Oorschot, B. van; Teufel, M.; Schuler, M.; Bausewein, C. und Tewes, M.
(2022):
The OUTREACH study: oncologists of German university hospitals in rotation on a palliative care unit-evaluation of attitude and competence in palliative care and hospice.
In: Journal of Cancer Research and Clinical Oncology, Bd. 149, Nr. 7: S. 2929-2936
2017
Knop, S.; Langer, C.; Engelhardt, M.; Mügge, L.-O.; Reichle, A.; Rösler, W.; Bassermann, F.; Hertenstein, B.; Kunitz, A.; Röllig, C.; Ostermann, H.; Schäfer-Eckart, K.; Ringhoffer, M.; Günther, A.; Junghanss, C.; Biersack, H.; Schreder, M.; Liebert, A.; Held, S.; Einsele, H. und Bargou, R. C.
(2017):
Lenalidomide, adriamycin, dexamethasone for induction followed by stem-cell transplant in newly diagnosed myeloma.
In: Leukemia, Bd. 31, Nr. 8: S. 1816-1819
Heckl, B. C.; Carlet, M.; Grunert, M.; Vick, B.; Roolf, C.; Junghanss, C.; Spiekermann, K.; Hiddemann, W. und Jeremias, I.
(2017):
Adult primary acute leukemia samples with chromosomal translocations grow well in immunodeficient mice, but are difficult to transduce with lentiviruses.
In: Haematologica, Bd. 102: S. 656-657
Heckl, B.; Carlet, M.; Grunert, M.; Vick, B.; Roolf, C.; Junghanss, C.; Spiekermann, K.; Hiddemann, W. und Jeremias, I.
(2017):
Primary Adult Acute Lymphoblastic Leukemic Cells Reliably Engraft and Grow in Immunodeficient Mice.
In: Annals of Hematology, Bd. 96:
S71-S72
Lange, T.; Krahl, R.; Grünhagen, U. von; Al-Ali, H. K.; Schwarzer, A.; Jentsch-Ullrich, K.; Spohn, C.; Lakner, V.; Assmann, M.; Junghanss, C.; Pfirrmann, M.; Gil, A.; Hehlmann, R.; Deininger, M. und Niederwieser, D.
(2017):
Imatinib (IM) in combination with Hydroxyurea in patients with CML1st CP does not increase molecular response at 18 months compared to IM alone. Final results of the OSHO CML2004 study. NCT 02480608.
In: Oncology Research and Treatment, Bd. 40: S. 121-122
Lange, T.; Krahl, R.; Grünhagen, U. vom; Al-Ali, H. K.; Schwarzer, A.; Uhle, R.; Spohn, C.; Lakner, V.; Assmann, M.; Junghanss, C.; Pfirrmann, M.; Gil, A.; Hehlmann, R.; Deininger, M. und Niederwieser, D.
(2017):
Imatinib (im) 400mg in patients with cml1st cp results in a higher molecular response rate at 6 months compared to im/hydroxyurea. Final results of the cml2004 study. Nct 02480608.
In: Haematologica, Bd. 102: S. 729-730